The role of epidermal growth factor receptor in prognosis and treatment of gastric cancer

Expert Review of Gastroenterology and Hepatology

Volumn 8, Issue 1, 2014, Pages 111-117

  Hong, Liu ^a   Han, Yu ^a   Brain, Lubi ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

epidermal growth factor receptor; gastric cancer; prognosis; target therapy

Indexed keywords

CAPECITABINE; CETUXIMAB; CISPLATIN; DACOMITINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; ERLOTINIB; FIGITUMUMAB; FIRTECAN; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MONOCLONAL ANTIBODY; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PERTUZUMAB; PF 04691502; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BRAIN ISCHEMIA; CANCER INHIBITION; CANCER PROGNOSIS; CELL CYCLE ARREST; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; DIARRHEA; DISEASE SPECIFIC SURVIVAL; DRUG FATALITY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TARGETING; FATIGUE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPOMAGNESEMIA; MOLECULAR MECHANICS; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; RASH; RECURRENCE FREE SURVIVAL; REVIEW; SKIN TOXICITY; STOMACH CANCER; STOMACH CARCINOGENESIS; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84893057569     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2014.844648     Document Type: Review

References (61)

1. Smyth EC, Cunningham D. Targeted therapy for gastric cancer. Curr. Treat. Options Oncol. 13(3), 377-389 (2012
2. Yarom N, Jonker DJ. The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer. Discov. Med. 11(57), 95-105 (2011
3. Weickhardt AJ, Price TJ, Chong G et al. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: Preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer. J. Clin. Oncol. 30(13), 1505-1512 (2012
4. Welsh JW, Komaki R, Amini A et al. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J. Clin. Oncol. 31(7), 895-902 (2013
5. Patel R, Leung HY. Targeting the EGFR-family for therapy: Biological challenges and clinical perspective. Curr. Pharm. Des. 18(19), 2672-2679 (2012
6. Troiani T, Martinelli E, Capasso A et al. Targeting EGFR in pancreatic cancer treatment. Curr. Drug Targets. 13(6), 802-810 (2012
7. Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, Batra SK. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin. Ther. Targets. 16(1), 15-31 (2012
8. Berg M, Soreide K. EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: Implications for targeted therapy. Discov. Med. 14(76), 207-214 (2012
9. Liakakos T, Fatourou E, Ziogas D, Lykoudis E, Roukos DH. Targeting VEGF, EGFR, and other interacting pathways for gastric cancer-promises and reality. Ann. Surg. Oncol. 15(10), 2981-2982 (2008
10. Smyth EC, Cunningham D. Targeted therapy for gastric cancer. Curr. Treat. Options Oncol. 13(3), 377-389 (2012
11. Okines A, Cunningham D, Chau I. Targeting the human EGFR family in esophagogastric cancer. Nat. Rev. Clin. Oncol. 8(8), 492-503 (2011
12. García I, Vizoso F, Martín A et al. Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann. Surg. Oncol. 10(3), 234-241 (2003
13. Ettinger DS. Clinical implications of EGFR expression in the development and progression of solid tumors: Focus on non-small cell lung cancer. Oncologist 11(4), 358-373 (2006
14. Kim JW, Kim HP, Im SA et al. The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. Cancer Lett. 272(2), 296-306 (2008
15. Inokuchi M, Murayama T, Hayashi M et al. Prognostic value of co-expression of STAT3, mTOR and EGFR in gastric cancer. Exp. Ther. Med. 2(2), 251-256 (2011
16. Terashima M, Kitada K, Ochiai A et al. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin. Cancer Res. 18(21), 5992-6000 (2012
17. Lieto E, Ferraraccio F, Orditura M et al. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann. Surg. Oncol. 15(1), 69-79 (2008
18. Atmaca A, Werner D, Pauligk C et al. The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer. BMC Cancer 12, 524 (2012
19. Matsubara J, Yamada Y, Hirashima Y et al. Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer. Clin. Cancer Res. 14(10), 3022-3029 (2008
20. Jácome AA, Wohnrath DR, Scapulatempo Neto C et al. Prognostic value of epidermal growth factor receptors in gastric cancer: A survival analysis by Weibull model incorporating long-Term survivors. Gastric Cancer. (doi:10.1007/ s10120-013-0236-z) (2013) (Epub ahead of print
21. Zhang J, Zhan Z, Wu J et al. Association among polymorphisms in EGFR gene exons, lifestyle and risk of gastric cancer with gender differences in Chinese han subjects. PLoS One 8(3), e59254 (2013
22. Han SW, Oh DY, Im SA et al. Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6. Cancer Sci. 101(3), 793-799 (2010
23. Moutinho C, Mateus AR, Milanezi F, Carneiro F, Seruca R, Suriano G. Epidermal growth factor receptor structural alterations in gastric cancer. BMC Cancer 8, 10 (2008
24. Liu Z, Liu L, Li M et al. Epidermal growth factor receptor mutation in gastric cancer. Pathology. 43(3), 234-238 (2011
25. Becker JC, Müller-Tidow C, Stolte M et al. Acetylsalicylic acid enhances antiproliferative effects of the EGFR inhibitor gefitinib in the absence of activating mutations in gastric cancer. Int. J. Oncol. 29(3), 615-623 (2006
26. Sakamoto N, Oue N, Sentani K et al. Liver-intestine cadherin induction by epidermal growth factor receptor is associated with intestinal differentiation of gastric cancer. Cancer Sci. 103(9), 1744-1750 (2012
27. Hirao T, Sawada H, Koyama F et al. Antisense epidermal growth factor receptor delivered by adenoviral vector blocks tumor growth in human gastric cancer. Cancer Gene Ther. 6(5), 423-427 (1999
28. Jiang L, Lan T, Chen Y et al. PKG II Inhibits EGF/EGFR-Induced Migration of Gastric Cancer Cells. PLoS One 8(4), e61674 (2013
29. Klein S, Levitzki A. Targeting the EGFR and the PKB pathway in cancer. Curr. Opin. Cell Biol. 21(2), 185-193 (2009
30. Merlo V, Longo M, Novello S, Scagliotti GV. EGFR pathway in advanced non-small cell lung cancer. Front. Biosci. (Schol. Ed.). 3, 501-517 (2011
31. Han W, Lo HW. Landscape of EGFR signaling network in human cancers: Biology and therapeutic response in relation to receptor subcellular locations. Cancer Lett. 318(2), 124-134 (2012
32. Liao G, Wang Z, Zhang N, Dong P. Dominant negative epidermal growth factor receptor inhibits growth of human gastric cancer cells by inducing cell cycle arrest and apoptosis. Cancer Biother. Radiopharm. (doi:10.1089/cbr.2012. 1399) (2013) (Epub ahead of print
33. Liao G, Wang Z, Zhao L, Zhang N, Dong P. Inhibitory effects of cytoplasmic-domain substituted epidermal growth factor receptor on growth, invasion and angiogenesis in human gastric cancer cells. Mol. Med. Rep. 3(2), 287-294 (2010
34. Caruso R, Pallone F, Fina D et al. Protease-Activated receptor-2 activation in gastric cancer cells promotes epidermal growth factor receptor trans-Activation and proliferation. Am. J. Pathol. 169(1), 268-278 (2006
35. Dan L, Jian D, Na L, Xiaozhong W. Crosstalk between EGFR and integrin affects invasion and proliferation of gastric cancer cell line, SGC7901. Onco Targets Ther. 5, 271-277 (2012
36. Norguet E, Dahan L, Seitz JF. Targetting esophageal and gastric cancers with monoclonal antibodies. Curr. Top. Med. Chem. 12(15), 1678-1682 (2012
37. Heindl S, Eggenstein E, Keller S et al. Relevance of MET activation and genetic alterations of KRAS and E-cadherin for cetuximab sensitivity of gastric cancer cell lines. J. Cancer Res. Clin. Oncol. (doi:10.1007/s00432-011-1128-4) (2012) (Epub ahead of print
38. Kneissl J, Keller S, Lorber T et al. Association of amphiregulin with the cetuximab sensitivity of gastric cancer cell lines. Int. J. Oncol. 41(2), 733-744 (2012
39. Hara M, Nakanishi H, Tsujimura K et al. Interleukin-2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor-overexpressing gastric cancer xenografts through antibody-dependent cellular cytotoxicity. Cancer Sci. 99(7), 1471-1478 (2008
40. Zhang J, Ji J, Yuan F et al. EGFR-blockade by antibody Cetuximab inhibits the growth of human gastric cancer xenograft in nude mice and its possible mechanism. Zhonghua Zhong Liu Za Zhi. 31(2), 85-89 (2000
41. Hotz B, Keilholz U, Fusi A, Buhr HJ, Hotz HG. In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype. Gastric Cancer. 15(3), 252-64 (2012
42. Luo HY, Wei W, Shi YX et al. Cetuximab enhances the effect of oxaliplatin on hypoxic gastric cancer cell lines. Oncol. Rep. 23(6), 1735-1745 (2010
43. Fukuda K, Saikawa Y, Takahashi M et al. Antitumor effect of cetuximab in combination with S-1 in EGFR-Amplified gastric cancer cells. Int. J. Oncol. 40(4), 975-982 (2012
44. Kobunai T, Watanabe T, Fukusato T. Antitumour activity of S-1 in combination with cetuximab on human gastric cancer cell lines in vivo. Anticancer Res. 31(11), 3691-3696 (2011
45. Yamashita-Kashima Y, Iijima S, Yorozu K et al. Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models. Clin. Cancer Res. 17(15), 5060-5070 (2011
46. Shiraishi K, Mimura K, Izawa S et al.; Lapatinib acts on gastric cancer through both antiproliferative function and augmentation of trastuzumab-mediated antibody-dependent cellular cytotoxicity. Gastric Cancer. (2012) (Epub ahead of print
47. Wainberg ZA, Anghel A, Desai AJ et al. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-Amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin. Cancer Res. 16(5), 1509-1519 (2010
48. LaBonte MJ, Manegold PC, Wilson PM et al. The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38. Int. J. Cancer. 125(12), 2957-2969 (2009
49. Shibata T, Kan H, Murakami Y et al. Y-box binding protein-1 contributes to both HER2/ErbB2 expression and lapatinib sensitivity in human gastric cancer cells. Mol. Cancer Ther. 12(5), 737-746 (2013
50. Yokoyama H, Ikehara Y, Kodera Y et al. Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis. Br. J. Cancer 95(11), 1504-1513 (2006
51. Kishida O, Miyazaki Y, Murayama Y et al. Gefitinib (Iressa, ZD1839) inhibits SN38-Triggered EGF signals and IL-8 production in gastric cancer cells. Cancer Chemother. Pharmacol. 55(4), 393-403 (2005
52. Zhu S, Belkhiri A, El-Rifai W. DARPP-32 increases interactions between epidermal growth factor receptor and ERBB3 to promote tumor resistance to gefitinib. Gastroenterology 141(5), 1738-1748 (2011
53. Piontek M, Hengels KJ, Porschen R, Strohmeyer G. Antiproliferative effect of tyrosine kinase inhibitors in epidermal growth factor-stimulated growth of human gastric cancer cells. Anticancer Res. 13(6A), 2119-2123 (1993
54. Nam HJ, Ching KA, Kan J et al. Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer. Mol. Cancer Ther. 11(2), 439-451 (2012
55. Chan JA, Blaszkowsky LS, Enzinger PC et al. A multicenter phase II trial of single-Agent cetuximab in advanced esophageal and gastric adenocarcinoma. Ann. Oncol. 22(6), 1367-1373 (2011
56. Lordick F, Luber B, Lorenzen S et al. Cetuximab plus oxaliplatin/ leucovorin/5-fluorouracil in first-line metastatic gastric cancer: A phase II study of the arbeitsgemeinschaft internistische onkologie (AIO). Br. J. Cancer. 102(3), 500-505 (2010
57. Wainberg ZA, Lin LS, DiCarlo B et al. Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction. Br. J. Cancer. 105(6), 760-765 (2011
58. Iqbal S, Goldman B, Fenoglio-Preiser CM et al. Southwest Oncology Group study S0413: A phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer. Ann. Oncol. 22(12), 2610-2615 (2011
59. Bamias A, Karina M, Papakostas P et al. A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. Cancer Chemother. Pharmacol. 65(6), 1009-1021 (2010
60. Waddell T, Chau I, Cunningham D et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): A randomised, open-label phase 3 trial. Lancet Oncol. 14(6), 481-489 (2013
61. Wei X. Mechanism of EGFR-related cancer drug resistance. Anticancer Drugs 22(10), 963-970 (2011